Immunomodulation is a private biopharmaceutical company focused on developing breakthrough therapies to modulate immune responses in multiple high value oncology and serious infectious disease indications.

Our lead program, Annexin V is in preclinical development for the treatment of breast cancer, listeria, Ebola, dengue and Marburg, and has the potential for additional pipeline expansion opportunities. Annexin V binds to phosphatidylserine (PS) on tumor cells and infective organisms, and has demonstrated to be effective in generating an immune response and showing tumor size reduction in comparative disease models.

We are working in collaboration with a network of leading institutions, including Stanford University and the University of South Alabama to drive the execution of our development plan and we expect to file an IND for Annexin V in less than 18 months.